Fortitude Family Office’s Genmab GMAB Stock Holding History

Fortitude Family Office’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-42	Closed	-$822	–	2067
2025 Q1	$822	Hold	42	–	–	﹤0.01%	1043
2024 Q4	$877	Buy	+42	New	+$923	﹤0.01%	1151

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Fortitude Family Office's GMAB Position: Q2 2025 in Review

Fortitude Family Office sold out of Genmab (GMAB) in Q2 2025, closing a stake of 42 shares — an estimated $822 sold.

Fortitude Family Office first reported a position in GMAB in Q4 2024 and held it in 2 quarters. The position peaked at $877 in Q4 2024. 217 funds tracked by Wall St. Rank hold GMAB as of Q2 2025.

Fortitude Family Office reported no remaining Genmab position as of Q2 2025 after selling out during the quarter.
Fortitude Family Office sold 42 Genmab shares in Q2 2025, an estimated $822.
Fortitude Family Office first reported a position in Genmab in Q4 2024 and held it in 2 quarters.
Fortitude Family Office's Genmab position peaked at $877 in Q4 2024.
217 funds tracked by Wall St. Rank held Genmab as of Q2 2025.

Based on Fortitude Family Office's 13F filing for Q2 2025, filed 15 Jul 2025.